Report on ivermectin prophylaxis in a hospital in Argentina showing lower cases for healthcare workers taking ivermectin. Preliminary results from: . Note that this prophylaxis trial is a different study to the early treatment Vallejos trial.
Vallejos et al., 12/20/2020, retrospective, Argentina, South America, preprint, 1 author, dosage 12mg weekly.
risk of COVID-19 case, 73.4% lower, RR 0.27, p < 0.001, treatment 13 of 389 (3.3%), control 61 of 486 (12.6%).
This study is excluded in meta analysis: detail too minimal.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.